CLINICAL_TRIALS
trial_result
· 2023-05-18
Clinical Trial Update: A 6 Month Safety Extension Study of MBGS205 [Phase 2]
Summary
Phase 2 safety extension study completed for MBGS205 in hypogonadotropic hypogonadism; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mereo BioPharma | Conditions: Hypogonadotropic Hypogonadism | Phase 2 | Status: COMPLETED | Results posted: 2023-05-18